OOIR: Observatory of International Research

Papers

(The H4-Index of Rheumatology is 38. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)

Article	Citations
P070 Evaluation of the perception of pediatric rheumatology by pediatric residents: results of a national survey	100
P137 Epidemiological study of influenza vaccination and RA	95
P205 The contemporary presentation and management of giant cell arteritis with large vessel vasculitis	94
Cardiovascular risk and mortality in rheumatoid arthritis compared with diabetes mellitus and the general population	92
67 Double impact: hypophosphatemic rickets and vitamin D intoxication	82
P018 Non-alcoholic fatty liver disease in spondyloarthritis: identifying patients on therapy at high risk of serious liver disease	81
P103 The impact of the COVID-19 pandemic on primary care referrals and new diagnoses of inflammatory arthritis	73
E053 Effectiveness of colchicine among patients with COVID-19 infection: a randomised, open labelled, clinical trial	72
E010 Checkpoint inhibitor-induced rheumatological adverse events: real-world experience from Northeast England	72
E078 Inflammation modifies the effect of rheumatoid arthritis in overall mortality among females	67
OA02 Real-world experience of dose tapering TNF inhibitors in rheumatoid arthritis: Long-term results	65
P107 Long-term efficacy of baricitinib in patients with rheumatoid arthritis with inadequate response to bDMARDs: results from RA-BEYOND up to 6.9-years of treatment	58
P186 Long-term safety of ixekizumab in adult patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis	58
P110 Challenges of meeting NICE guidance for rheumatoid arthritis in the modern era: a service audit	53
P045 Development and evaluation of machine learning algorithms for the prediction of opioid-related deaths among UK patients with non-cancer pain	52
E063 Cardiac amyloidosis: a case series of 31 patients with a comprehensive literature review	50
E058 The effects of a pain management programme for patients with an inflammatory arthritis	50
P139 Rituximab in a large UK centre during the COVID-19 pandemic: the effects of employing a reduced dosing regimen on clinical response in Rheumatoid Arthritis patients	48
P193 Bimekizumab improves key symptoms, disease activity and function in patients across the full spectrum of axial spondyloarthritis up to week 24: results from two phase 3 studies	47
P007 Automating blood monitoring and handover for patients with rheumatic diseases commencing disease-modifying anti-rheumatic drugs (DMARDs)	47
P166 Parotid benign lymphoepithelial cyst in connective tissue disease: a rare case series and literature review	47
P104 The role of occupational therapy for the self-management of rheumatoid arthritis: a mixed methods systematic review	47
P071 Exercise as an anti-inflammatory treatment in axial spondyloarthritis (axSpA): a proof-of-concept study	47
E027 An outlandish presentation of IgG4-related disease	46
P012 Using the BSR Lupus audit as a springboard to improve management of SLE in the outpatient clinic	46

P068 The effects of exercise and physical activity in inflammatory rheumatic diseases: a scoping literature review	44
P054 Utilising a pharmacist-designed best value biologic and targeted synthetic shared decision-making tool to empower patients, support clinicians and save NHS resources	44
P010 Real world experience of switching to an adalimumab biosimilar; different outcomes for axial spondylitis, psoriatic and rheumatoid arthritis	43
P124 Rheumatoid Arthritis with Normal CRP: an Underappreciated, Persistent Phenotype: Equally at Risk of Severe Disease	42
P105 Mode of hospital rheumatology appointments in people with rheumatoid arthritis: the impact of the pandemic in England	42
P183 Disease activity, comorbidities and functional status predict treatment response to biologic and targeted synthetic disease-modifying anti-rheumatic drugs in psoriatic arthritis	42
P053 Patient engagement in long-term PROMs collection: 48-month observation in real-world clinical practice	41
OA03 Harnessing quantitative proteomics to identify biomarkers of treatment response to etanercept in patients with rheumatoid arthritis	41
P095 Fibromyalgia correlates with neurodivergent traits in a self-selected community population	41
OA17 Patient values and what matters to patients with axial spondyloarthritis in clinic	40
P198 Intracardiac thrombosis and vascular involvement in Behçet's disease: two sides of the same coin?	40
P056 Analysis of antibody response to SARS-CoV-2 vaccination and natural infection in a tertiary centre cohort of lupus nephritis patients	38
P127 Baricitinib Efficacy in Moderate Rheumatoid Arthritis - A Post-hoc Analysis from two Phase III Trials	38
E011 What information should we provide to inform and empower our patients to participate in shared decision making? The patient perspective	38
OA32 Jaw claudication - does the textbook description need updating?	38
E072 Real-world single-centre experience of JAK inhibitor use in RA	38